 [1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ERYTHROMYCIN ETHYLSUCCINATE increase or decrease[0m
[34mthe risk of aplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ERYTHROMYCIN ETHYLSUCCINATE increase the risk of aplastic anemia?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ERYTHROMYCIN ETHYLSUCCINATE increase the risk of[0m
[32maplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ERYTHROMYCIN ETHYLSUCCINATE increase the risk of aplastic anemia?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ERYTHROMYCIN ETHYLSUCCINATE increase the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"ERYTHROMYCIN ETHYLSUCCINATE"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: references: REFERENCES Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, the American Heart [0m
[31mAssociation: Prevention of Rheumatic Fever. Circulation. [0m[1;31m78[0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m:[0m[1;31m1082[0m[31m-[0m[1;31m1086[0m[31m, October [0m[1;31m1988[0m[31m. Honein, M.A., et al.: Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromycin: a [0m
[31mcase review and cohort study. ERYTHROMYCIN ETHYLSUCCINATE: references: The Lancet [0m[1;31m1999[0m[31m;[0m[1;31m354[0m[31m [0m[1;31m([0m[1;31m9196[0m[1;31m)[0m[31m: [0m[1;31m2101[0m[31m-[0m[1;31m5[0m[31m         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: information_for_patients: Information for Patients Patients should be counseled that antibacterial drugs including Ery-Ped should only be used to treat bacterial [0m
[31minfections. They do not treat viral infections [0m[1;31m([0m[31me.g., the common cold[0m[1;31m)[0m[31m. When Ery-Ped is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better [0m
[31mearly in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m decrease the effectiveness of the immediate [0m
[31mtreatment and [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m increase the likelihood that bacteria will develop resistance and will not be treatable by Ery-Ped or other antibacterial drugs in the future. Diarrhea is a common problem caused by [0m
[31mantibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools [0m[1;31m([0m[31mwith or without stomach cramps [0m
[31mand fever[0m[1;31m)[0m[31m even as late as two or more months after having taken the last dose of the antibiotic. ERYTHROMYCIN ETHYLSUCCINATE: information_for_patients: If this occurs, patients should contact their [0m
[31mphysician as soon as possible.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: spl_product_data_elements: Ery-Ped Erythromycin Ethylsuccinate CARAMEL POLYSORBATE [0m[1;31m80[0m[31m SODIUM CITRATE, UNSPECIFIED FORM SUCROSE XANTHAN GUM ERYTHROMYCIN [0m
[31mETHYLSUCCINATE ERYTHROMYCIN Ery-Ped Erythromycin Ethylsuccinate CARAMEL POLYSORBATE [0m[1;31m80[0m[31m SODIUM CITRATE, UNSPECIFIED FORM SUCROSE XANTHAN GUM ERYTHROMYCIN ETHYLSUCCINATE ERYTHROMYCIN         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: clinical_pharmacology: CLINICAL PHARMACOLOGY Orally administered erythromycin ethylsuccinate suspension is readily and reliably absorbed under both fasting and [0m
[31mnonfasting conditions. Erythromycin diffuses readily into most body fluids. Only low concentrations are normally achieved in the spinal fluid, but passage of the drug across the blood-brain barrier [0m
[31mincreases in meningitis. In the presence of normal hepatic function, erythromycin is concentrated in the liver and excreted in the bile; the effect of hepatic dysfunction on excretion of erythromycin [0m
[31mby the liver into the bile is not known. Less than [0m[1;31m5[0m[31m percent of the orally administered dose of erythromycin is excreted in active form in the urine. Erythromycin crosses the placental barrier, but [0m
[31mfetal plasma levels are low. The drug is excreted in human milk. ERYTHROMYCIN ETHYLSUCCINATE: microbiology: Microbiology Mechanism of Action Erythromycin acts by inhibition of protein synthesis by [0m
[31mbinding [0m[1;31m50[0m[31m S ribosomal subunits of susceptible organisms. It does not affect nucleic acid synthesis. Antagonism has been demonstrated in vitro between erythromycin and clindamycin, lincomycin, and [0m
[31mchloramphenicol. Resistance Many strains of Haemophilus influenzae are resistant to erythromycin alone but are susceptible to erythromycin and sulfonamides used concomitantly. Interactions With Other [0m
[31mAntimicrobials Staphylococci resistant to erythromycin may emerge during a course of therapy. Antimicrobial Activity Erythromycin has been shown to be active against most strains of the following [0m
[31mmicroorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section. ERYTHROMYCIN ETHYLSUCCINATE: microbiology: Gram-positive Organisms: Corynebacterium [0m
[31mdiphtheriae Corynebacterium minutissimum Listeria monocytogenes Staphylococcus aureus [0m[1;31m([0m[31mresistant organisms may emerge during treatment[0m[1;31m)[0m[31m Streptococcus pneumoniae Streptococcus pyogenes Gram-negative [0m
[31mOrganisms: Bordetella pertussis Legionella pneumophila Neisseria gonorrhoeae Other Microorganisms: Chlamydia trachomatis Entamoeba histolytica Mycoplasma pneumoniae Treponema pallidum Ureaplasma [0m
[31murealyticum The following in vitro data are available. Erythromycin exhibits in vitro minimal inhibitory concentrations [0m[1;31m([0m[31mMIC's[0m[1;31m)[0m[31m of [0m[1;31m0[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: openfda: spl_set_id         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: openfda: brand_name         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: openfda: generic_name         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: openfda: package_ndc         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: carcinogenesis_and_mutagenesis_and_impairment_of_fertility: Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term oral dietary studies conducted with [0m
[31merythromycin stearate in rats up to [0m[1;31m400[0m[31m mg/kg/day and in mice up to [0m[1;31m500[0m[31m mg/kg/day [0m[1;31m([0m[31mapproximately [0m[1;31m1[0m[31m-[0m[1;31m2[0m[31m fold of the maximum human dose on a body surface area basis[0m[1;31m)[0m[31m did not provide evidence of [0m
[31mtumorigenicity. Erythromycin stearate did not show genotoxic potential in the Ames, and mouse lymphoma assays or induce chromosomal aberrations in CHO cells. There was no apparent effect on male or [0m
[31mfemale fertility in rats treated with erythromycin base by oral gavage at [0m[1;31m700[0m[31m mg/kg/day [0m[1;31m([0m[31mapproximately [0m[1;31m3[0m[31m times the maximum human dose on a body surface area basis[0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: general_precautions: General Prescribing Ery-Ped in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to [0m
[31mprovide benefit to the patient and increases the risk of the development of drug-resistant bacteria. Since erythromycin is principally excreted by the liver, caution should be exercised when [0m
[31merythromycin is administered to patients with impaired hepatic function. [0m[1;31m([0m[31mSee CLINICAL PHARMACOLOGY and WARNINGS sections.[0m[1;31m)[0m[31m Exacerbation of symptoms of myasthenia gravis and new onset of symptoms of [0m
[31mmyasthenic syndrome has been reported in patients receiving erythromycin therapy. There have been reports of infantile hypertrophic pyloric stenosis [0m[1;31m([0m[31mIHPS[0m[1;31m)[0m[31m occurring in infants following erythromycin [0m
[31mtherapy. ERYTHROMYCIN ETHYLSUCCINATE: general_precautions: In one cohort of [0m[1;31m157[0m[31m newborns who were given erythromycin for pertussis prophylaxis, seven neonates [0m[1;31m([0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m developed symptoms of non-bilious [0m
[31mvomiting or irritability with feeding and were subsequently diagnosed as having IHPS requiring surgical pyloromyotomy . A possible dose-response effect was described with an absolute risk of IHPS of [0m
[1;31m5.1[0m[31m% for infants who took erythromycin for [0m[1;31m8[0m[31m-[0m[1;31m14[0m[31m days and [0m[1;31m10[0m[31m% for infants who took erythromycin for [0m[1;31m15[0m[31m-[0m[1;31m21[0m[31m days. [0m[1;31m2[0m[31m Since erythromycin may be used in the treatment of conditions in infants which are [0m
[31massociated with significant mortality or morbidity [0m[1;31m([0m[31msuch as pertussis or neonatal Chlamydia trachomatis infections[0m[1;31m)[0m[31m, the benefit of erythromycin therapy needs to be weighed against the potential risk [0m
[31mof developing IHPS. Parents should be informed to contact their physician if vomiting or irritability with feeding occurs. ERYTHROMYCIN ETHYLSUCCINATE: general_precautions: Prolonged or repeated use [0m
[31mof erythromycin may result in an overgrowth of nonsusceptible bacteria or fungi. If superinfection occurs, erythromycin should be discontinued and appropriate therapy instituted. When indicated, [0m
[31mincision and drainage or other surgical procedures should be performed in conjunction with antibiotic therapy. Observational studies in humans have reported cardiovascular malformations after exposure[0m
[31mto drug products containing erythromycin during early pregnancy. ERYTHROMYCIN ETHYLSUCCINATE: precautions: PRECAUTIONS General Prescribing Ery-Ped in the absence of a proven or strongly suspected [0m
[31mbacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. Since erythromycin is principally [0m
[31mexcreted by the liver, caution should be exercised when erythromycin is administered to patients with impaired hepatic function. [0m[1;31m([0m[31mSee CLINICAL PHARMACOLOGY and WARNINGS sections.[0m[1;31m)[0m[31m Exacerbation of [0m
[31msymptoms of myasthenia gravis and new onset of symptoms of myasthenic syndrome has been reported in patients receiving erythromycin therapy. There have been reports of infantile hypertrophic pyloric [0m
[31mstenosis [0m[1;31m([0m[31mIHPS[0m[1;31m)[0m[31m occurring in infants following erythromycin therapy. ERYTHROMYCIN ETHYLSUCCINATE: precautions: Prolonged or repeated use of erythromycin may result in an overgrowth of nonsusceptible [0m
[31mbacteria or fungi. If superinfection occurs, erythromycin should be discontinued and appropriate therapy instituted. When indicated, incision and drainage or other surgical procedures should be [0m
[31mperformed in conjunction with antibiotic therapy. Observational studies in humans have reported cardiovascular malformations after exposure to drug products containing erythromycin during early [0m
[31mpregnancy. Information for Patients Patients should be counseled that antibacterial drugs including Ery-Ped should only be used to treat bacterial infections. They do not treat viral infections [0m[1;31m([0m[31me.g.,[0m
[31mthe common cold[0m[1;31m)[0m[31m. When Ery-Ped is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be [0m
[31mtaken exactly as directed.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32m DO-NOT-KNOW[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ERYTHROMYCIN ETHYLSUCCINATE increase the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ERYTHROMYCIN ETHYLSUCCINATE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does ERYTHROMYCIN ETHYLSUCCINATE increase the risk [0m
[31mof aplastic anemia?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mI have asked FDAHandler about the relationship between [0m
[32mERYTHROMYCIN ETHYLSUCCINATE and the risk of aplastic anemia. However, I have not yet received a response that would allow me to provide an informed answer. Therefore, at this moment, I must state that[0m
[32mI do not know whether ERYTHROMYCIN ETHYLSUCCINATE increases or decreases the risk of aplastic anemia. If FDAHandler provides information later, I will be able to update this answer accordingly.[0m
 [1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.USER [0m
*[1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m          [1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Do one of the following:[0m

[31m        [0m[1;31m1[0m[31m. If you intend to ask a question to FDAAgent:[0m
[31m            Please use the [0m[31m'add_recipient'[0m[31m tool/function-call[0m
[31m            and specify FDAAgent as your `intended_recipient`.[0m
[31m            DO NOT REPEAT your original message; ONLY specify the [0m
[31m            `intended_recipient` via this tool/function-call.[0m
[31m        [0m[1;31m2[0m[31m. If you are ready to have the critic check your answer,[0m
[31m            do so with the `final_answer` tool/function, as I have requested.[0m
[31m        [0m[1;31m3[0m[31m. If the critic is satisfied and you intend to submit your final answer,[0m
[31m            answer as I have requested, making sure to mark that you are done as usual.[0m

[31m        When you have decided and stated your answer [0m[1;31m([0m[31mor lack of one[0m[1;31m)[0m[31m, you must[0m
[31m        ALWAYS specify that you are done using the usual code.[0m

[31m        DO NOT simply acknowldedge these instructions. If you have nothing[0m
[31m        else to say, you MUST EXIT IMMEDIATELY by stating that you are done[0m
[31m        with the usual code [0m[1;31m([0m[31mas in #[0m[1;31m3[0m[1;31m)[0m[31m.[0m
[31m        [0m
 [1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0madd_recipient[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"add_recipient"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mI have asked FDAHandler about the relationship [0m
[32mbetween ERYTHROMYCIN ETHYLSUCCINATE and the risk of aplastic anemia. However, I have not yet received a response that would allow me to provide an informed answer. Therefore, at this moment, I must [0m
[32mstate that I do not know whether ERYTHROMYCIN ETHYLSUCCINATE increases or decreases the risk of aplastic anemia. If FDAHandler provides information later, I will be able to update this answer [0m
[32maccordingly.[0m
 [1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mI have asked FDAHandler about the relationship between ERYTHROMYCIN ETHYLSUCCINATE and the risk of [0m
[34maplastic anemia. However, I have not yet received a response that would allow me to provide an informed answer. Therefore, at this moment, I must state that I do not know whether ERYTHROMYCIN [0m
[34mETHYLSUCCINATE increases or decreases the risk of aplastic anemia. If FDAHandler provides information later, I will be able to update this answer accordingly.[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mYour task is to answer questions about various documents.[0m
[32mYou will be given various passages from these documents, and asked to answer questions [0m
[32mabout them, or summarize them into coherent answers.[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mDocumentHandler[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m                Do one of the following:[0m
[31m                [0m[1;31m1[0m[31m. Search for relevant text using one of the following tools/functions:[0m
[31m                    `relevant_extracts`, `relevant_search_extracts`, and `drug_category_search`[0m
[31m                [0m[1;31m2[0m[31m. If you could not find an answer, state that you are done and DO-NOT-KNOW[0m
[31m                    as usual[0m
[31m                [0m[1;31m3[0m[31m. If you have found an answer, state that you are done and express the answer[0m
[31m                    as usual[0m
[31m                [0m[1;31m4[0m[31m. If you have no clear remaining question to answer, answer the original[0m
[31m                    question as in #[0m[1;31m3[0m[31m, and if there was no original question, respond[0m
[31m                    as in #[0m[1;31m2[0m

[31m                If you have been getting or sending repeated messages, always exit by[0m
[31m                stating that you are done [0m[1;31m([0m[31musing the usual code[0m[1;31m)[0m[31m and say DO-NOT-KNOW.[0m

[31m                DO NOT simply acknowldedge these instructions. If you have nothing[0m
[31m                else to say, you are done and you MUST EXIT IMMEDIATELY by stating that you are done[0m
[31m                with the usual code [0m[1;31m([0m[31myou MUST choose #[0m[1;31m2[0m[31m or #[0m[1;31m3[0m[31m, and #[0m[1;31m4[0m[31m specifies how to choose[0m[1;31m)[0m[31m.[0m
[31m                THIS IS VERY IMPORTANT. DO THIS IMMEDIATELY BEFORE WAITING FOR ANY FURTHER MESSAGES.[0m
[31m                [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does ERYTHROMYCIN ETHYLSUCCINATE increase or decrease the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I attempted to ask FDAHandler whether ERYTHROMYCIN ETHYLSUCCINATE increases the risk of aplastic anemia, but I did not receive a response."[0m[32m,[0m
[32m      [0m[32m"Without information from FDAHandler, I cannot provide an evidence-based answer."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does ERYTHROMYCIN ETHYLSUCCINATE increase or decrease the risk of aplastic anemia?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I attempted to ask FDAHandler whether ERYTHROMYCIN ETHYLSUCCINATE increases the risk of aplastic anemia, but I did not receive a response."[0m[34m,[0m
[34m      [0m[34m"Without information from FDAHandler, I cannot provide an evidence-based answer."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does ERYTHROMYCIN ETHYLSUCCINATE increase or decrease the risk of aplastic anemia?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I attempted to ask FDAHandler whether ERYTHROMYCIN ETHYLSUCCINATE increases the risk of aplastic anemia, but I did not receive a response.[0m
[1;31m2[0m[31m. Without information from FDAHandler, I cannot provide an evidence-based answer.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-aplastic anemia-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mI attempted to ask FDAHandler whether ERYTHROMYCIN ETHYLSUCCINATE increases the risk of aplastic anemia, but I did not receive a response. Without information from FDAHandler, I cannot provide an [0m
[32mevidence-based answer. Therefore, my final answer is that I do not know whether ERYTHROMYCIN ETHYLSUCCINATE increases or decreases the risk of aplastic anemia.[0m
